

DOC-19 VACCINATION

To combat the pandemic

Content Outline

Topics for discussion

01 Introduction

02 Intro To our database

03 Basic Mockup

04 Conclusion



What is DOC-19 VACCINATION


Database system that will help hospital manage:


1.Vaccines2.Certificate3.User



DOC-19

For Fast and Effective Approach






To be able to effectively manage all this aspect will help save lives

— 5. Hengsamrithiphol


BASIC ER DIAGRAM















Login Page






Register Page



tegister		
	First Name	
First	Name	
	Middle Name	
Mdd	Middle Name	
	Last Name	
Last	Name	
	Gender	3
.54	fect your Gender 🗸	9
Sec.	National ID	-
PARCE	Passport ID	
Dura	port ID	_
	be: 10/16/2021	
Deline	Address	63
Addr		7
Production of the Control of the Con	E-Mail	
E-Mi	il Address	
	Contact No.	_
(+66)	
	SUBMIT	

Vaccine Information Page



DOC-19

VACCINE INFORMATION

BOOKING

VACCINE CERTIFICATED LOG OUT

Vaccine Information

Sinovac



CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and Covaxin, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2-8 °C (36-46 °F), temperatures at which flu vaccines are kept. A real-world study of tens of millions of Chileans who received CoronaVac found it 66% effective against symptomatic COVID-19, 86% against hospitalization, 90% against ICU admissions, and 86% against deaths. In Brazil, after 75% of the population in Serrana, São Paulo, received CoronaVac, preliminary results show deaths fell by 95%, hospitalizations by 86%, and symptomatic cases by 80%. In Indonesia, real world data from 128,290 healthcare workers showed 94%: protection against symptomatic infection by the vaccine, beating results in clinical trials. Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials. Phase III results from Brazil previously showed 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of 21 days or more between the doses [16] CoronaVac is being used in vaccination campaigns in various countries in Asia, South America, Central America, and Eastern Europe. By April 2021. Sinovac had a production capacity of 2 billion doses a year. It is currently being manufactured at several facilities in China, with planned overseas manufacture in Brazil in September 2021 and eventually in Egypt and Hungary, On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use. Sinovac has signed purchase agreements for 380 million doses from COVAX. As of July 2021, CoronaVac was the most widely used COVID-19 vaccine in the world, with 943 million doses delivered.

Pfizer

Booking Page

To allow more flexibility

The patient will be able to choose their appointment by themselve




VACCINE INFORMATION


BOOKING

VACCINE CERTIFICATED

LOG OUT



Vaccine Certificate



DOC-19

VACCINE INFORMATION

BOOKING

VACCINE CERTIFICATE LOG OUT

Vaccines Certificate

First Name: xretax

Middle Name: ss

Last Name: haha

Gender: Male

Birth Date: 2021-11-01

Vaccine: Pfizer

Dose: 1

Date: 2021-10-16

Vaccination Site: Future Park Rangsit



Criteria for success

Flexibility

Minor changes can be made according to the situation

Safety

The Patient my be able to safely use this database without leaks

Efficiency

This tools must be fast to use for both staff and patient

Questions or comments?

Get in touch!

DOC-19 GROUP

Any questions feel free to ask.

